Imlunestrant

Modify Date: 2024-01-02 22:45:42

Imlunestrant Structure
Imlunestrant structure
Common Name Imlunestrant
CAS Number 2408840-26-4 Molecular Weight 524.51
Density N/A Boiling Point N/A
Molecular Formula C29H24F4N2O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Imlunestrant


Imlunestrant (LY3484356) is an orally active selective estrogen receptor (ER) degrader (SERD). Imlunestrant (LY3484356) could be used in the study for ER+, HER2-advanced breast cancer[1].

 Names

Name Imlunestrant

 Imlunestrant Biological Activity

Description Imlunestrant (LY3484356) is an orally active selective estrogen receptor (ER) degrader (SERD). Imlunestrant (LY3484356) could be used in the study for ER+, HER2-advanced breast cancer[1].
Related Catalog
In Vitro Imlunestrant (LY3484356) shows favorable efficacy and pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants[1]. Imlunestrant (LY3484356) is a potent degrader and selective pure antagonist of wild type and mutant ERα[2].
References

[1]. Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.

[2]. Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812.

 Chemical & Physical Properties

Molecular Formula C29H24F4N2O3
Molecular Weight 524.51